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that some events not captured here could have altered the
statistical conclusions. As 10 patients had both limbs en-
rolled in this cohort, nonindependence of the patient and at
least some of the anatomic characteristics could have af-
fected the statistical conclusions. The total implant length
variable was chosen to encapsulate both disease severity and
intraoperative decision making, which differs from length
of the treated segment. Due to a lack of uniform use of
angiographic distance markers in this series, lesion length
was not available for analysis.
CONCLUSIONS
Reintervention rates following Viabahn treatment for
FPOD were40% within the first year, and more than half
of the observed clinical events were MALE. TASC D le-
sions, small-diameter (5 mm) devices, number and
summed length of devices implanted, and distal collateral
coverage are adverse factors to be carefully considered in
patient selection and intraoperative decision making. Our
results suggest particular caution in the treatment of clau-
dicants who have multiple unfavorable anatomic character-
istics for stent grafts as outlined herein. The importance of
dual-antiplatelet therapy after Viabahn graft placement
seems paramount. Further studies are needed to clarify the
clinical effectiveness of covered stents in the treatment of
FPOD; however, our results provide insights to guide the
application of this technology until higher-quality data are
available.
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Dr Gregory L. Moneta (Portland Ore). This study is retro-
spective, so we expect some data to be missing. Some deficiencies
are expected and, to the author’s credit, acknowledged. However,
there are some very basic data missing. We really don’t know howion. Follow-up is best described as inconsistent and the authors
ould not provide quantitative information on patency; although
y implication, patency was poor. There is no information on
uality of life. There is no cost information with respect to the
nitial procedure. We don’t know if wounds healed or walking
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Volume 56, Number 4 Johnston et al 1007were not candidates for more traditional treatments, such as a good
old fashioned vein bypass! Overall, we get the impression the
procedures were performed without careful ongoing assessment of
results similar to those cardiologists and interventional radiologists
we were all so critical of 15 years ago. As they say, “we have looked
at the enemy and he is us!” On a more serious note, in my opinion,
evaluation of a new procedure in one’s practice requires a height-
ened level of vigilance that seems to be lacking here.
What has this study confirmed? It confirms Willard Johnson’s
data from, I believe, the early 90s, that smaller-caliber prosthetic
grafts for treatment of femoral popliteal occlusive disease do not do
well. Category: “Wheel: reinvention of”! It certainly confirms my
bias that prosthetic devices of any sort for infrainguinal occlusive
disease remain suboptimal and best avoided if possible. The study
does confirm these devices can be reliably placed with a high
technical success rate, although one would have to ask with the
data presented, why you would want to?
We have confirmed that the Rutherford classification of limb
ischemia needs to be seriously reassessed. No so-called critically
ischemic limb in this series ended up with an amputation despite
all the graft failures. Perhaps these were not necessarily all that
critically ischemic limbs? Finally, we have basically confirmed
there is no free lunch in vascular surgery. Even in the endovas-
cular era, failure still comes with a price and a really good
small-caliber arterial substitute remains the Holy Grail of vas-
cular surgery.
However, we have learned a few things; some good, some bad.
We have learned, with a little effort, we can apparently change the
natural history of the limb in patients with claudication to be
similar to that of the natural history of the limb in patients with
critical limb ischemia. That is not a good thing. We have learned
engineers continue to be smarter than biochemists. Engineers
can design clever devices, but the biochemists still have not
figured out how to stop the intimal hyperplasia induced by these
clever devices. Endovascular therapy for infrainguinal occlusive
disease is going to get better. Despite all the marketing, how-
ever, real improvement will not occur until the biochemists
catch up with the engineers.
What is good? The paper is well written. The author’s obser-
vations on implant length/number and diameter, on coverage of
collateral vessels and the potential utility of dual-antiplatelet ther-
apy are of real importance and should be taken seriously by anyoneishing to implant these devices. The analysis of the data that is
vailable is honest and first rate.
I have a few questions:
. Is there still enthusiasm for this procedure at UCSF?
. There are some longer term risks with dual-antiplatelet therapy.
What proportion of peripheral arterial disease patients can
tolerate aspirin and clopidogrel long term? Have you any sug-
gestion as to when to stop dual-antiplatelet therapy, if ever?
. Would you use a good arm vein over this stent graft in a patient
with critical limb ischemia?
. Follow-up is a problem for anyone doing clinical research,
especially retrospective clinical research. What are you doing to
improve follow-up in your patients? Dr Johnston now works at
Kaiser in Denver. I look to Kaiser to help us with preventative
medicine. Do you do anything different at Kaiser with respect
to patient follow-up than was done at UCSF?
Dr Paul C. Johnston.DrMoneta, thank you for your honest
nd critical appraisal.
. I would have to confirm that, yes, enthusiasm for this pro-
cedure has waned at UCSF. After we started seeing some of
these patients come back with acute limb ischemia, red flags
started going up, and that was the impetus for starting this
project. Once the data were collected and analyzed, it further
changed our perspective.
. This is an unanswered question. Although we have anecdotally
not seen major bleeding complications with dual-antiplatelet
therapy, this study was not designed to capture all bleeding
events that may have occurred outside of our direct care. There is
no clear time point based on our data when the appropriate time
point to stop dual-antiplatelet therapymay be. As a result, we have
kept patients on both agents unless a contraindication arises.
. Therapy has to be individually tailored. In a patient with a
reasonable life expectancy and the ability to tolerate a poten-
tially lengthy procedure under general anesthesia, arm vein is a
good option.
. At Kaiser, we do benefit from a more closed system than exists at
many university hospitals such as UCSF. The electronic medical
record and finite set of care providers facilitates ongoing follow-up
both in terms of in-person office visits and surveillance studies.We
are also taking coordinated steps toward establishing surveillance
protocols andpatient registries for all permanent implants. There is
an unmet need to establish registry databases that we can all use to
better track patient outcomes.
